Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials

References

• World Health Organization – WHO. Available from http://www.who.int [Last accessed 8 April 2006]
   Google Scholar
• Wells KB, Stewart A, Hays RD, et al. The functioning and well being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989;262:659–60
   Google Scholar
• Zheng D, Macera CA, Croft JB, et al. Major depression and all-cause mortality among white adults in the United States. Ann Epidemiol 1997;7:213–8
   PubMed Web of Science ®Google Scholar
• Kind P, Sorenson J. The costs of depression. Int Clin Psychopharmacol 1993;7:191–5
   PubMed Web of Science ®Google Scholar
• Vis PM, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005;39:1798–807
   PubMed Web of Science ®Google Scholar
• Montes JM, Ferrando L, Saiz-Ruiz J. Remission in major depression with two antidepressant mechanisms: results from a naturalistic study. J Affect Disord 2004;79:229–34
   Google Scholar
• Mace M, Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin Pharmacother 2000;1:917–33
   PubMedGoogle Scholar
• Machado M, Iskedjian M, Einarson TR. Clinical comparison of SSRIs and SNRIs in major depressive disorder. Value Health 2005;8:A209
   Google Scholar
• Einarson TR, Addis A, Mittmann N, et al. Meta-analysis of venlafaxine, SSRIs and TCAs in the treatment of major depressive disorder. Can J Clin Pharmacol 1998;5:205–16
   Google Scholar
• Einarson TR, Arikian SR, Casciano J, et al. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999;21:296–308
   PubMed Web of Science ®Google Scholar
• Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851–5
   Google Scholar
• Diagnostic and statistical manual of mental disorders. 3rd edn., revised. Washington, DC: American Psychiatric Association, 1987
   Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be more sensitive to change. Br J Psychiatry 1979;43:382–9
   Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62
   PubMed Web of Science ®Google Scholar
• Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as example. Clin Ther 1997;19:559–69
   PubMed Web of Science ®Google Scholar
• Rosenthal R. Meta-analysis in the social sciences. Beverly Hills, CA: Sage Publications, 1984
   Google Scholar
• Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101–29
   Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101
   PubMed Web of Science ®Google Scholar
• Allard P, Gram L, Timdahl K, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 2004;19:1123–30
   PubMed Web of Science ®Google Scholar
• Amore M, Bellini M, Berardi D, et al. Double-blind comparison of fluvoxamine and imipramine in depressed patients. Curr Ther Res 1989;46:815–20
   Web of Science ®Google Scholar
• Ansseau M, von Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacol 1989;98:163–8
   PubMed Web of Science ®Google Scholar
• Ansseau M, Papart P, Troisfontaines B, et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacol 1994;114:131–7
   PubMed Web of Science ®Google Scholar
• Baca E, Garcia-Garcia M, Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol 2004;28:57–65
   Google Scholar
• Baca E, Gonzalez DC, Garcia-Toro M, et al. Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study. Prog Neuropsychopharmacol 2003;27:493–500
   Google Scholar
• Ballus C, Quiros G, De Flores T, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 2000;15:43–8
   PubMed Web of Science ®Google Scholar
• Braconnier A, Le Coent R, Cohen D, et al. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. J Am Acad Child Adol Psychiatry 2003;42:22–9
   PubMed Web of Science ®Google Scholar
• Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry 1985;46:32–7
   PubMed Web of Science ®Google Scholar
• Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985;46:26–31
   PubMed Web of Science ®Google Scholar
• Cohn JB, Wilcox C. Paroxetine in major depression: a double-blind trial with imipramine and placebo. J Clin Psychiatry 1992;53:52–6
   PubMed Web of Science ®Google Scholar
• de Jonghe F, Swinkels J, Tuynman-Qua H. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry 1991;24:21–7
   Google Scholar
• Demyttenaere K, Albert A, Mesters P, et al. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? J Clin psychiatry 2005;66:859–63
   PubMed Web of Science ®Google Scholar
• Feighner JP. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. J Clin psychiatry 1985;46:369–72
   PubMed Web of Science ®Google Scholar
• Khan MNS. Comparison of escitalopram a new SSRI with TCA, clomipramine in major depressive disorder: A double blind study. Pakistan J Medical Sci 2004;20:238–41
   Google Scholar
• Manna V, Martucci N, Agnoli A. Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders. Int Clin Psychopharmacol 1989;4:81–8
   Google Scholar
• March JS, Kobak KA, Jefferson JW, et al. A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in out-patients with major depression. J Clin psychiatry 1990;51:200–2
   PubMed Web of Science ®Google Scholar
• Mehtonen OP, Sogaard J, Roponen P, et al. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry 2000;61: 95–100
   Google Scholar
• Pintor L, Gasto C, Navarro V, et al. Relapse of major depression after complete and partial remission during a 2-year follow-up. J Affect Disord 2003;73:237–44
   PubMed Web of Science ®Google Scholar
• Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 1999;175:12–6
   PubMed Web of Science ®Google Scholar
• Schnyder U, Koller-Leiser A. A double-blind, multicentre study of paroxetine and maprotiline in major depression. Can J Psychiatry 1996;41:239–44
   PubMed Web of Science ®Google Scholar
• Shrivastava RK, Shrivastava SH, Overweg N, et al. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. J Clin Psychiatry 1992;53:48–51
   PubMed Web of Science ®Google Scholar
• Stuppaeck CH, Geretsegger C, Whitworth AB, et al. Multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994;14:241–6
   PubMed Web of Science ®Google Scholar
• Wehmeier PM, Kluge M, Maras A, et al. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients. Pharmacopsychiatry 2005;38:13–6
   PubMed Web of Science ®Google Scholar
• Dawson MY, Michalak EE, Waraich P, et al. Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis. BMC Family Practice 2004;7:5–19
   Google Scholar
• Ghaeli P, Ananloo ES, Avarsaji MK, et al. Comparing the effects of fluoxetine and imipramine on serum triglyceride and cholesterol levels in patients with major depressive disorder. ASHP Midyear Clinical Meeting 2005;36:INTL–95
   Google Scholar
• Mallick R, Chen J, Entsuah AR, et al. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. J Clin Psychiatry 2003;64:321–30
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Watkin JG, Liu C, et al. Duloxetine in the treatment of major depressive disorder: a comparison of efficacy in patients with and without melancholic features. BMC Psychiatry 2005;5:12
   PubMed Web of Science ®Google Scholar
• Rajagopalan M. Comparison of venlafaxine and imipramine in depressive illness. Acta Psychiatr Scand 1998;97:384–5
   PubMed Web of Science ®Google Scholar
• Ropert R. Fluoxetine versus clomipramine in major depressive disorders. Int Clin Psychopharmacol 1989;4:89–95
   PubMed Web of Science ®Google Scholar
• Shelton C, Entsuah R, Padmanabhan SK, et al. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol 2005;20:233–8
   PubMed Web of Science ®Google Scholar
• Silverstone PH, Entsuah R, Hackett D. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. Int Clin Psychopharmacol 2002;17:273–80
   Google Scholar
• Tamminen TT, Lehtinen VV. A double-blind parallel study to compare fluoxetine with doxepin in the treatment of major depressive disorders. Int Clin Psychopharmacol 1989;4:51–6
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah R, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Ital J Psychopathol 2002;8:362–9
   Google Scholar
• Beasley CM Jr, Sayler ME, Potvin JH. Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. Int Clin Psychopharmacol 1993;8:143–9
   Google Scholar
• Gu NF, Li HF, Shu L, et al. Extended release venlafaxine in treatment of major depression: a double-blind, randomized, and controlled multicentre study. Zhongguo Xinyao Yu Linchuang Zazhi 2002;21:66–71
   Google Scholar
• Gentil, V. Kerr-Correa F, Moreno R, et al. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Clin Psychopharmacol 2000;14:61–6
   Google Scholar
• Hwang JP, Yang CH, Tsai SJ. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients. Int J Geriatr Psychiatry 2004;19:189–90
   Google Scholar
• Quitkin FM, McGrath PJ, Stewart JW, et al. Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. J Clin Psychiatry 2005;66:670–6
   PubMed Web of Science ®Google Scholar
• Tzanakaki M, Guazzelli M, Nimatoudis I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 2000;15:29–34
   PubMed Web of Science ®Google Scholar
• Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord 1990;18: 289–99
   Google Scholar
• Amerongen APV, Ferrey G, Tournoux A. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. J Affect Disord 2002:72:21–31
   Google Scholar
• Arminen SL, Ikonen U, Pulkkinen P, et al. A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients. Acta Psychiatr Scand 1994;89:382–9
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry 1993;5:199–207
   Google Scholar
• Benedictis E. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol 2000;14:61–6
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190–6
   Google Scholar
• Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo and paroxetine controlled trial. Eur Neuropsychopharmacol 2004;14:457–70
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389–99
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225–31
   PubMed Web of Science ®Google Scholar
• Kyle CJ, Petersen HE, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8:147–53
   Google Scholar
• Leinonen E, Lepola U, Koponen H, et al. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 1997;96:497–504
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiol 2004;50:57–64
   Google Scholar
• Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171–81
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002;59: 233–9
   PubMed Web of Science ®Google Scholar
• Tignol J, Pujol-Domenech J, Chartres JP, et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatrica Scand 1998;97:157–65
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234–41
   Google Scholar
• European College of Neuropsychopharmacology. Age and gender likely to impact upon the treatment of depression. Pharm J 2003;271:556
   Google Scholar